Oral insulin has been a long-running peptide drug-delivery target. The field has tried and failed for decades to make insulin survive the gut at therapeutic dose. Recent work on this site covers Vivtex's permeability platform, Biocon's oral-insulin candidate work, and a small set of academic programs using novel salt-permeation enhancers.
The orforglipron precedent matters: now that small-molecule oral GLP-1 is approved, the case for forcing peptide insulin orally weakens commercially. The remaining clinical path tends to focus on patient adherence in T1D and select T2D populations.
Stories here cover platform readouts and any movement toward late-stage trials. See #drug-delivery for the broader oral peptide thread.
A team at Kumamoto University led by Associate Professor Shingo Ito developed a cyclic peptide (D-DNP-V) that ferries insulin across the small intestine. Combined with zinc-stabilized insulin hexamers and given orally to diabetes models, the platform rapidly normalized blood sugar with once-daily dosing for three consecutive days. A click-chemistry-conjugated DNP-insulin molecule performed equivalently, substantially reducing the high doses that have historically plagued oral insulin.
Kumamoto University's DNP cyclic peptide system achieved roughly one-third to nearly half the effectiveness of injected insulin in animal studies — a major advance for oral insulin delivery.
Kumamoto University researchers developed cyclic peptide D-DNP-V that escorts insulin through the gut, achieving one-third to nearly half the effectiveness of injected insulin in mice.
Kumamoto University researchers developed a cyclic peptide (DNP peptide) that enables oral insulin delivery through the intestinal wall — a dramatic improvement that could end the century-long dependence on injections.